Giao dịch Alto Neuroscience Inc - ANRO CFD

Alto Neuroscience Inc. (NYSE: ANRO) is a California-based biopharmaceutical company developing personalised treatments for mental health conditions. It focuses on innovative therapies for major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and schizophrenia, with promising drug candidates like ALTO-100 and ALTO-300. The company is also pioneering a biomarker-based platform to tailor treatments, using patient-specific biological data to improve outcomes. Since its founding in 2019, Alto Neuroscience has been at the forefront of personalised mental health care.